

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Armistead et al.

Serial No.:

09/685,053

Group Art Unit: 1624

Filed:

October 6, 2000

Examiner:

V. Balasubramanian

For:

KINASE INHIBITORS

Docket No.:

A-748E

AMENDMENT AND RESPONSE

The Commissioner of Patents and Trademarks Washington, D.C. 20231

Dear Sir:

In response to the Office Action dated December 17, 2001, rejecting Claims 1-31 of the above-identified application, reconsideration and withdrawal of the outstanding rejections are respectfully requested. Applicants amend the subject application as follows:

In the Claims

Cancel claims 30-31, without prejudice.

Amend Claims 1-29, as follows:

1. A compound having the formula:

wherein,

Each R¹ and R² is independently R³; R⁸; NHR³; NHR⁵; NHR⁶; NR⁵R⁵; NR⁵R⁶; SR⁵; SR⁶; SR³; OR⁵; OR⁶; OR³; C(O)R³; heterocyclyl optionally substituted with 1-4 independent R⁴ on each ring; or C1-C10 alkyl substituted with 1-4 independent R⁴;